Latest Heparin Stories
The Medicines Company (NASDAQ:MDCO) today announced the presentation of a new analysis of data from the HORIZONS-AMI trial demonstrating that major bleeding contributes to more deaths at 30 days than repeat heart attack, or re-infarction, in severe heart attack patients treated with angioplasty.
Japan-based pharmaceutical company Daiichi Sankyo Company has announced positive data from the clinical study of DU-176b, an oral anticoagulant that directly inhibits Factor Xa, a clotting factor in the blood.
MUNICH, Germany, Sept. 2 /PRNewswire/ -- Regado Biosciences, Inc. announced today the presentation of comprehensive results from Phase Ia, Ib and Ic studies of the Company's REG1 Anticoagulation System at the European Society of Cardiology's Congress 2008, currently being held in Munich, Germany.
By Fareed, J Iqbal, O; Cunanan, J; Demir, M; Wahi, R; Clarke, M; Adiguzel, C; Bick, R The conventional management of thrombotic and cardiovascular disorders is based on the use of heparin, oral anticoagulants and aspirin.
Larger amounts of fully synthetic heparin could be ready for use in patients in 5 years
Maximus, a business unit of leading infusion therapy firm Medegen Inc., today announced that as a result of a Co-Marketing Agreement between C.R.
SAN CARLOS, Calif., Aug. 14 /PRNewswire-FirstCall/ -- Nuvelo, Inc.
U.S. health officials say they have been able to connect three deaths to a contaminated batch of the blood-thinning drug heparin.